ASLAN Pharmaceuticals Presents New Data From Phase 2b Study

Data presented during the late-breaker oral presentation of the TREK-AD study demonstrate e blasakimab’s potential as the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with

Related Keywords

California , United States , Russia , Singapore , Oregon , Ukraine , Ericl Simpson , Francesj Storrs , Ashleyr Robinson , Alex Kaoukhov , Emma Thompson , Exchange Commission On , Spurwing Communications , Linkedin , Exchange Commission , Science University , Pharmaceuticals Nasdaq , European Academy Of Dermatology , Company Us Securities , Commission File No , Lifesci Advisors , Oregon Health , Venereology Congress , Company Annual Report On Form , European Academy , Medical Dermatology , Lead Investigator , Eczema Area , Severity Index , Chief Medical Officer , Investigator Global Assessment , Atopic Dermatitis , San Mateo , Sci Advisors , Commission File , Annual Report , Region ,